Commercial Versus PARTNER Study Experience With the Transfemoral Edwards SAPIEN Valve for Inoperable Patients With Severe Aortic Stenosis - 02/01/14
Abstract |
In patients with aortic stenosis who cannot have surgery, transcatheter aortic valve replacement using the Edwards SAPIEN valve has been shown to improve survival rate and is approved for commercial use in the United States. This study aims to assess the clinical profile, procedural characteristics, and in-hospital complications in patients treated with a commercial SAPIEN valve outside the clinical trial context. We retrospectively analyzed 69 consecutive patients who underwent transcatheter aortic valve replacement with a commercial SAPIEN valve compared with 55 Placement of AoRTic traNscathetER valves (PARTNER) trial patients from cohort B enrolled in the same institution by the same Heart Team. Compared with the commercial group, patients in the PARTNER cohort B had higher mean Society of Thoracic Surgeons score (10 ± 5 vs 9 ± 4, p = 0.04) and a lower rate of peripheral arterial disease (19% vs 44%, p = 0.004). Most patients in the commercial group had the procedure under conscious sedation (83% vs 66%, p = 0.03). Planned surgical cut down for vascular access was rare in the commercial group (1.4% vs 46%, p <0.001). The overall rates of major vascular complications, life-threatening or major bleeding, and blood transfusions were lower in commercial group (7.2% vs 27%, p = 0.003; 2.9% vs 16%, p = 0.01; and 28% vs 60%, p <0.001, respectively). In-hospital all-cause mortality (5.8% vs 9.1%, p = 0.51) and stroke rates (7.2% vs 14.5%, p = 0.19) were not statistically different between groups. The median length of hospitalization (p <0.001) and postprocedural length of stay (p = 0.01) was shorter in the commercial group. In conclusion, transfemoral commercial use of the Edwards SAPIEN valve for inoperable patients shows similar in-hospital mortality and stroke rates compared with PARTNER cohort B. The refinements in the procedure such as more conscious sedation, experience of the operators, and careful vascular planning in the commercial group led to lesser vascular and bleeding complications and shorter length of stay.
Le texte complet de cet article est disponible en PDF.Plan
| See page 346 for disclosure information. |
Vol 113 - N° 2
P. 342-347 - janvier 2014 Retour au numéro
Article précédent
- Prediction of 30-Day Heart Failure-Specific Readmission Risk by Echocardiographic Parameters
- Paaladinesh Thavendiranathan, Teerapat Yingchoncharoen, Andrew Grant, Sinziana Seicean, Steven H. Landers, Eiran Z. Gorodeski, Thomas H. Marwick
- Outcome of Transcatheter Aortic Valve Implantation in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction
- Simon Biner, Edo Yaakov Birati, Yan Topilsky, Arie Steinvil, Eyal Ben Assa, Ben Sadeh, Yaron Arbel, Amir Halkin, Yigal Abramowitz, Eran Leshem-Rubinow, Shmuel Banai, Gad Keren, Ariel Finkelstein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?